Ribosome-Targeting Antibiotics Impair T Cell Effector Function and Ameliorate Autoimmunity by Blocking Mitochondrial Protein Synthesis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Almeida, LuísDhillon-LaBrooy, Ayesha
Castro, Carla N
Adossa, Nigatu
Carriche, Guilhermina M
Guderian, Melanie
Lippens, Saskia
Dennerlein, Sven
Hesse, Christina
Lambrecht, Bart N
Berod, Luciana
Schauser, Leif
Blazar, Bruce R
Kalesse, Markus
Müller, Rolf
Moita, Luís F
Sparwasser, Tim
Issue Date
2020-11-24
Metadata
Show full item recordAbstract
While antibiotics are intended to specifically target bacteria, most are known to affect host cell physiology. In addition, some antibiotic classes are reported as immunosuppressive for reasons that remain unclear. Here, we show that Linezolid, a ribosomal-targeting antibiotic (RAbo), effectively blocked the course of a T cell-mediated autoimmune disease. Linezolid and other RAbos were strong inhibitors of T helper-17 cell effector function in vitro, showing that this effect was independent of their antibiotic activity. Perturbing mitochondrial translation in differentiating T cells, either with RAbos or through the inhibition of mitochondrial elongation factor G1 (mEF-G1) progressively compromised the integrity of the electron transport chain. Ultimately, this led to deficient oxidative phosphorylation, diminishing nicotinamide adenine dinucleotide concentrations and impairing cytokine production in differentiating T cells. In accordance, mice lacking mEF-G1 in T cells were protected from experimental autoimmune encephalomyelitis, demonstrating that this pathway is crucial in maintaining T cell function and pathogenicity.Citation
Immunity. 2021 Jan 12;54(1):68-83.e6. doi: 10.1016/j.immuni.2020.11.001. Epub 2020 Nov 24.Affiliation
HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.;HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
Elsevier (Cell Press)Journal
ImmunityPubMed ID
33238133Type
ArticleLanguage
enEISSN
1097-4180ae974a485f413a2113503eed53cd6c53
10.1016/j.immuni.2020.11.001
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- Ribosome shifting or splitting: it is all up to the EF-G.
- Authors: Christian B, Haque E, Spremulli L
- Issue date: 2009 Aug 28
- Mitochondrial translation factors of Trypanosoma brucei: elongation factor-Tu has a unique subdomain that is essential for its function.
- Authors: Cristodero M, Mani J, Oeljeklaus S, Aeberhard L, Hashimi H, Ramrath DJ, Lukeš J, Warscheid B, Schneider A
- Issue date: 2013 Nov
- EF-G2mt is an exclusive recycling factor in mammalian mitochondrial protein synthesis.
- Authors: Tsuboi M, Morita H, Nozaki Y, Akama K, Ueda T, Ito K, Nierhaus KH, Takeuchi N
- Issue date: 2009 Aug 28
- Dysfunctional mitochondrial translation and combined oxidative phosphorylation deficiency in a mouse model of hepatoencephalopathy due to Gfm1 mutations.
- Authors: Molina-Berenguer M, Vila-Julià F, Pérez-Ramos S, Salcedo-Allende MT, Cámara Y, Torres-Torronteras J, Martí R
- Issue date: 2022 Jan
- Identification of elongation factor G as the conserved cellular target of argyrin B.
- Authors: Nyfeler B, Hoepfner D, Palestrant D, Kirby CA, Whitehead L, Yu R, Deng G, Caughlan RE, Woods AL, Jones AK, Barnes SW, Walker JR, Gaulis S, Hauy E, Brachmann SM, Krastel P, Studer C, Riedl R, Estoppey D, Aust T, Movva NR, Wang Z, Salcius M, Michaud GA, McAllister G, Murphy LO, Tallarico JA, Wilson CJ, Dean CR
- Issue date: 2012